Our webinar with Dr. Tina Duong remains timely and important for families with FSHD. In it, she focuses on individuals with early-onset FSHD, meaning those who develop symptoms in their… Read More »
About early-onset FSHD
European FSHD patients speak out
To coincide with World Rare Disease Day FSHD Patients across Europe say what they want from clinical trials Announcement by FSHD Europe FSHD Europe is pleased to publish the Lay… Read More »
Vita Therapeutics seeks volunteers
Participate in a research study on a muscle regenerating treatment for FSHD Vita Therapeutics is a cell engineering company harnessing the power of genetics to develop cellular medicines in the… Read More »
Avidity gets orphan drug designation
Avidity Biosciences announced this week that it had received FDA Orphan Drug Designation for its experimental FSHD treatment, called AOC 1020. This does NOT mean the drug is now available… Read More »
FDA Fast Track Designation for Avidity’s FSHD therapeutic
What does this mean for patients? An FDA Fast Track designation DOES NOT mean that the drug has been approved for use by patients. AOC 1020 is still a long… Read More »